Recordati Industria Chimica e Farmaceutica S.p.A.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Recordati Industria Chimica e Farmaceutica S.p.A. - overview
Established
1926
Location
Milan, -, Italy
Primary Industry
Pharmaceuticals
About
Founded in 1926 and based in Milan, Italy, Recordati Industria Chimica e Farmaceutica S. p. A. develops, manufactures and markets pharmaceutical products used for the treatment of rare diseases.
The firm also offers pharmaceutical chemicals, such as active pharmaceutical ingredients and intermediates. In 1984, Recordati Industria Chimica e Farmaceutica S. p. A.
was listed in the Italian Stock Exchange under the ticker symbol RECI. In December 2021, Recordati S. p. A.
, a portfolio company of CVC Capital Partners, Public Sector Pension Investment Board, and StepStone, agreed to fully acquire EUSA Pharma (UK) Limited for EUR 750 million. Recordati mainly engages in the manufacture and development of rare treatment diseases. Recordati owns and operates several brands in Italy as well as Russia, Turkey, US, Japan, etc. Some of the brands that are under Recordati includes Carbaglu, Cosmegen, Cystadane, etc.
Current Investors
Public Sector Pension Investment Board, StepStone, CVC
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development, Specialty Pharmaceuticals, Medicinal Chemicals & Botanicals
Website
www.recordati.com/
Verticals
Manufacturing
Company Stage
Mature - Growth Capital
Total Amount Raised
Subscriber access only
Recordati Industria Chimica e Farmaceutica S.p.A. - timeline of key events
Recordati Industria Chimica e Farmaceutica S.p.A. - financials
| Fiscal Year Ended | Dec 31, 2010 | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 240,898,078 | 267,457,514 | 273,150,523 | 288,136,724 | 282,489,678 | 297,438,073 | 320,706,360 | 371,007,812 | 448,740,256 | 440,918,589 | 449,375,943 | 464,719,000 | - | - | - |
| % Revenue Growth (YoY) | - | 11.0% | 2.1% | 5.5% | (2.0%) | 5.3% | 7.8% | 15.7% | 21.0% | (1.7%) | 1.9% | 3.4% | - | - | - |
| EBITDA (USD) | 43,346,719 | 51,536,316 | 46,868,039 | 54,239,285 | 53,428,228 | 61,559,934 | 84,021,857 | 116,052,027 | 174,255,634 | 156,503,679 | 177,844,656 | 123,841,000 | - | - | - |
| Operating Income (USD) | 33,617,255 | 43,641,794 | 39,350,251 | 45,854,809 | 44,864,143 | 52,443,790 | 74,595,804 | 101,461,794 | 152,175,170 | 132,064,506 | 152,600,656 | 123,841,000 | - | - | - |
| Operating Margin | 14.0% | 16.3% | 14.4% | 15.9% | 15.9% | 17.6% | 23.3% | 27.3% | 33.9% | 30.0% | 34.0% | 26.6% | - | - | - |
| % EBITDA Margin | 18.0% | 19.3% | 17.2% | 18.8% | 18.9% | 20.7% | 26.2% | 31.3% | 38.8% | 35.5% | 39.6% | 26.6% | - | - | - |
| NET Income (USD) | 67,892,227 | 78,461,982 | 85,032,199 | 73,573,476 | 88,926,182 | 125,515,545 | 110,102,226 | 212,505,744 | 217,330,294 | 241,091,949 | 234,663,914 | 219,109,000 | - | - | - |
| % Net Margin | 28.2% | 29.3% | 31.1% | 25.5% | 31.5% | 42.2% | 34.3% | 57.3% | 48.4% | 54.7% | 52.2% | 47.1% | - | - | - |
Recordati Industria Chimica e Farmaceutica S.p.A. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Private Placement/Follow on | Completed | Recordati Industria Chimica e Farmaceutica S.p.A. | - | ||||||||
| Add-on, Trade Sale | Completed | EUSA Pharma (UK) Limited | - | ||||||||
| PIPE | Completed | Recordati Industria Chimica e Farmaceutica S.p.A. | - | ||||||||
| Trade Sale | Completed | Italchimici SPA | - | ||||||||
| Trade Sale | Completed | Opalia Pharma S.A. | - |
Displaying 1 - 5 of 8
Recordati Industria Chimica e Farmaceutica S.p.A. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.